Recent Updates
Recently added Catalysts

Fluticasone propionate

Phase 3

Seasonal Allergic Rhinitis | Small molecule | Respiratory |AstraZeneca PLC|Last Updated: Jan 24, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment750

FDA Designations

No designations recorded

Clinical trial landscape

Fluticasone propionate · 1 trial · 1 indication

Phase 3 1
NCT00641680Rhinocort Aqua Versus Placebo and Fluticasone PropionateSeasonal Allergic Rhinitis
COMPLETED750 Analytics
PHASE3COMPLETED
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
Seasonal Allergic Rhinitis
NCT00641680750
Unlock trial analytics

Study Endpoints

Primary Endpoints

To compare once daily treatment with Rhinocort against placebo and at reliving the nasal symptoms of seasonal allergic rhinitis.
2 weeks

Secondary Endpoints

To compare once daily treatment with Rhinocort against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
2 weeks
To compare once daily treatment with placebo against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
2 weeks
Safety assessment via adverse events and clinical measurements.
2 & 4 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALBudesonide
2ACTIVE_COMPARATORFluticasone propionate
3PLACEBO_COMPARATOR -

Interventions

NameTypeDescription
BudesonideDRUG -
Fluticasone propionateDRUG -
PlaceboDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range12 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * At least a 2 year documented history of seasonal allergic rhinitis * who, in the opinion of the investigator, * is a candidate for treatment with nasal steroids based on a history of either * a)inadequate control of symptoms with antihistamines, decongestants and/or immunot...

Unlock Eligibility Criteria

Frequently asked questions about Fluticasone propionate

What is Fluticasone propionate used for?

Fluticasone propionate is used for the treatment of seasonal allergic rhinitis. It is a small molecule respiratory therapy being developed by AstraZeneca PLC. The drug is currently in Phase 3 clinical development and is being studied in a randomized, double-blind, placebo-controlled trial.

Who makes Fluticasone propionate?

Fluticasone propionate is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is being studied for the treatment of seasonal allergic rhinitis and is currently in Phase 3 clinical development.

What phase is Fluticasone propionate in?

Fluticasone propionate is in Phase 3 clinical development. It is being investigated for the treatment of seasonal allergic rhinitis. The drug is not yet approved and remains investigational, with an ongoing clinical trial program evaluating its safety and efficacy.

What clinical trials is Fluticasone propionate in?

Fluticasone propionate is being studied in a Phase 3 clinical trial with the identifier NCT00641680. This trial is titled 'Rhinocort Aqua Versus Placebo and Fluticasone Propionate' and has completed enrollment of 750 participants aged 12 years and older with seasonal allergic rhinitis. The study is randomized, double-blind, and placebo-controlled.

Is Fluticasone propionate the same as Rhinocort Aqua?

Fluticasone propionate is being compared to Rhinocort Aqua in a clinical trial. The Phase 3 study NCT00641680 is titled 'Rhinocort Aqua Versus Placebo and Fluticasone Propionate,' indicating that the two are distinct treatments being evaluated against each other for seasonal allergic rhinitis.